Tina Hartert

A clinical trial supports approval of a new medication to treat moderate-to-severe asthma in children.
April 24, 2023

Study finds early RSV infection linked to significantly increased risk of asthma in children

A Vanderbilt study has found that RSV infection in the first year of life is associated with a significantly increased risk of asthma in children.

March 9, 2023

Study finds RSV may evade vaccines via rapid mutation

A Vanderbilt study concluded that RSV’s ability to mutate rapidly to escape detection by the body’s immune system makes it more challenging to design and develop vaccines that can stop it from spreading.

A clinical trial supports approval of a new medication to treat moderate-to-severe asthma in children.
July 21, 2022

Study explores role RSV plays in later asthma development

A Vanderbilt clinical project will follow 1,950 Middle Tennessee children to determine how genes and the environment interact with RSV infection during the first year of life and contribute to asthma development

June 3, 2022

Food allergy linked to lower risk of SARS-CoV-2 infection

May 12, 2020

Study to determine rate of novel coronavirus infection in U.S. children

Researchers at Vanderbilt University Medical Center (VUMC) are leading a nationwide study to determine the rate of novel coronavirus infection in U.S. children and their families.

July 12, 2018

Team explores diabetes drug’s ability to treat RSV infection

A drug used to treat diabetes may point to new therapies for respiratory syncytial virus (RSV) bronchiolitis — inflammation and obstruction of the lungs’ small airways. A multi-disciplinary team of Vanderbilt investigators has demonstrated that liraglutide reduces the inflammatory response to RSV infection in a mouse model of the disease.